The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2015

Filed:

Dec. 05, 2012
Applicant:

Washington University, St. Louis, MO (US);

Inventors:

Matthew L. Becker, St. Louis, MO (US);

Huafeng Fang, St. Louis, MO (US);

Xiaoxu Li, St. Louis, MO (US);

Dipanjan Pan, St. Louis, MO (US);

Raffaella Rossin, St. Louis, MO (US);

Xiankai Sun, St. Louis, MO (US);

John Stephen Taylor, St. Louis, MO (US);

Jeffrey L. Turner, St. Louis, MO (US);

Michael John Welch, St. Louis, MO (US);

Karen L. Wooley, St. Louis, MO (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 51/00 (2006.01); A61M 36/14 (2006.01); A61K 31/7088 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 51/12 (2006.01); B82Y 5/00 (2011.01); B82Y 30/00 (2011.01);
U.S. Cl.
CPC ...
A61K 31/7088 (2013.01); A61K 51/1251 (2013.01); C12N 15/111 (2013.01); C12N 15/1135 (2013.01); B82Y 5/00 (2013.01); B82Y 30/00 (2013.01); C01P 2004/64 (2013.01); C12N 2310/11 (2013.01); C12N 2310/3181 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3513 (2013.01); C12N 2310/3517 (2013.01); C12N 2320/10 (2013.01); C12N 2320/31 (2013.01);
Abstract

A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2'-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.


Find Patent Forward Citations

Loading…